Literature DB >> 10903959

Effects of riluzole on electrically evoked neurotransmitter release.

T Jehle1, J Bauer, E Blauth, A Hummel, M Darstein, T M Freiman, T J Feuerstein.   

Abstract

1. The main purpose of the present study was to investigate the effects of the neuroprotective agent riluzole on the electrically evoked release of [(3)H]-glutamate ([(3)H]-Glu) in mouse neocortical slices. The reported selectivity of riluzole for excitatory amino acids was tested in release experiments with further neurotransmitters. Also distinct species, mouse, rat and man were compared. 2. [(3)H]-Glu was formed endogenously during incubation of slices with [(3)H]-glutamine ([(3)H]-Gln). Released [(3)H]-Glu and tissue [(3)H]-Glu was separated by anion exchange chromatography. Electrically evoked [(3)H]-Glu release was strongly diminished by tetrodotoxin (TTX) and Ca(2+)-withdrawal. 3. Riluzole (100 microM) depressed the release of [(3)H]-Glu up to 77% (IC(50)=19.5 microM). Riluzole was also able to inhibit strongly the electrically evoked release of [(3)H]-acetylcholine ([(3)H]-ACh) (at 100 microM by 92%, IC(50)=3.3 microM, and [(3)H]-dopamine ([(3)H]-DA) (at 32 microM by 72%, IC(50)=6.8 microM). However, the release of [(3)H]-serotonin ([(3)H]-5-HT) was less diminished (at 100 microM by 53%, IC(50)=39.8 microM). Riluzole up to 100 microM did not affect [(3)H]-noradrenaline ([(3)H]-NA) release. 4. Between species, i.e. in mouse, rat and human neocortex, no significant differences between the effects of riluzole could be observed. 5. The NMDA-receptor blocker MK-801 (1 microM) and the AMPA/Kainate-receptor blocker NBQX (1 microM) did neither affect the electrically evoked [(3)H]-ACh release nor its inhibition by riluzole, indicating that effects of riluzole on transmitter release were neither due to modulation of ionotropic Glu receptors, nor due to indirect inhibition of Glu release through these receptors. 6. Taken together, riluzole inhibits the release of distinct neurotransmitters differently, but is not selective for the excitatory amino acid Glu.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903959      PMCID: PMC1572184          DOI: 10.1038/sj.bjp.0703424

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

1.  Riluzole specifically blocks inactivated Na channels in myelinated nerve fibre.

Authors:  E Benoit; D Escande
Journal:  Pflugers Arch       Date:  1991-12       Impact factor: 3.657

2.  Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake.

Authors:  M Szatkowski; B Barbour; D Attwell
Journal:  Nature       Date:  1990-11-29       Impact factor: 49.962

3.  Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.

Authors:  C Malgouris; F Bardot; M Daniel; F Pellis; J Rataud; A Uzan; J C Blanchard; P M Laduron
Journal:  J Neurosci       Date:  1989-11       Impact factor: 6.167

4.  Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes.

Authors:  M W Debono; J Le Guern; T Canton; A Doble; L Pradier
Journal:  Eur J Pharmacol       Date:  1993-04-28       Impact factor: 4.432

5.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action.

Authors:  J P Hubert; J C Delumeau; J Glowinski; J Prémont; A Doble
Journal:  Br J Pharmacol       Date:  1994-09       Impact factor: 8.739

7.  Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischaemia.

Authors:  J Pratt; J Rataud; F Bardot; M Roux; J C Blanchard; P M Laduron; J M Stutzmann
Journal:  Neurosci Lett       Date:  1992-06-22       Impact factor: 3.046

8.  Riluzole inhibits the release of glutamate in the caudate nucleus of the cat in vivo.

Authors:  A Chéramy; L Barbeito; G Godeheu; J Glowinski
Journal:  Neurosci Lett       Date:  1992-12-07       Impact factor: 3.046

9.  The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.

Authors:  D Martin; M A Thompson; J V Nadler
Journal:  Eur J Pharmacol       Date:  1993-12-21       Impact factor: 4.432

10.  Release of endogenous glutamate from rat cortical slices in presence of the glutamate uptake inhibitor L-trans-pyrrolidine-2,4-dicarboxylic acid.

Authors:  P C Waldmeier; P Wicki; J J Feldtrauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

View more
  20 in total

1.  Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder.

Authors:  Vladimir Coric; Snezana Milanovic; Suzanne Wasylink; Pinal Patel; Robert Malison; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2003-03-26       Impact factor: 4.530

2.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

3.  Preclinical evaluation of riluzole: assessments of ethanol self-administration and ethanol withdrawal symptoms.

Authors:  Joyce Besheer; Veronique Lepoutre; Clyde W Hodge
Journal:  Alcohol Clin Exp Res       Date:  2009-08       Impact factor: 3.455

4.  Molecular mechanisms of interaction between the neuroprotective substance riluzole and GABA(A)-receptors.

Authors:  K Jahn; F Schlesinger; L J Jin; R Dengler; J Bufler; K Krampfl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-05-06       Impact factor: 3.000

5.  Hydrogen peroxide modulates synaptic transmission in ventral horn neurons of the rat spinal cord.

Authors:  Masayuki Ohashi; Toru Hirano; Kei Watanabe; Keiichi Katsumi; Nobuko Ohashi; Hiroshi Baba; Naoto Endo; Tatsuro Kohno
Journal:  J Physiol       Date:  2015-12-07       Impact factor: 5.182

6.  Riluzole in the prelimbic medial prefrontal cortex attenuates veratrine-induced anxiety-like behaviors in mice.

Authors:  Masanori Ohashi; Akiyoshi Saitoh; Misa Yamada; Jun-Ichiro Oka; Mitsuhiko Yamada
Journal:  Psychopharmacology (Berl)       Date:  2014-08-17       Impact factor: 4.530

Review 7.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

Review 8.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

Review 10.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.